*1.What is your name?(Required.)

First Name

Last Name

*2.What is your degree?(Required.)

MD/DO

PA

NP

RN

Other (please specify)

*3.What is your specialty?(Required.)

Dermatology

Immunology

Internal Medicine

Family Practice/PCP

Other (please specify)

*4.How confident are you in the management of patients with Prurigo Nodularis (PN) in your practice?(Required.)

Very confident

Confident

Neutral

Little confidence

No confidence

*5.Angela, a 45-year-old female, presents with raised nodules on her legs and lower back. She complains of itch, anxiety/embarrassment, pain, and inability to sleep. If you suspect PN, which should be the primary treatment goal to improve her quality of life? (Required.)

Controlling pruritus

Enhancing sleep

Improving psychological health

Relieving pain

*6.In assessing Angela, her dermatologist notes there are 23 palpable lesions. What level of severity would this indicate using the IGA scale for PN?(Required.)

Almost clear

Mild

Moderate

Severe

*7.The neural-immune dysregulation believed to be at the core of PN pathogenesis is characterized primarily by which markers of Th2 inflammation?(Required.)

CGRP and BDNF

IL-4/IL-13, and IL-31

PAR2 and PGE2

IL-6 and IL-12

*8.Angela’s dermatologist diagnosed PN and initially prescribed a topical corticosteroid and antidepressant to which Angela had insufficient response. Which of the following off-label therapies do the 2021 AAD guidelines recommend as Tier 3 treatment for moderate-to-severe PN?(Required.)

Gabapentin or pregabalin

Intralesional corticosteroids

NK1 receptor antagonists

Dupilumab or nemolizumab

*9.Findings from the phase 3 PRIME 2 trial of dupilumab in PN that were released at the 2022 AAD meeting in March showed the biologic met its primary endpoint (improvement by ≥4 points in Worst Itch-Numeric Rating Scale [WI-NRS]) by almost 58% over placebo at which time point?(Required.)

Week 12

Week 24

Week 48

Week 52